Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy ANN ARBOR, MICHIGAN // Apr. 8, 2019 – HistoSonics, developer of a non-invasive robotics platform and novel beam therapy, announced today that it has closed …
Latest News From Lumira Ventures
Medexus Pharmaceuticals Inc. (CVE:MDP) Revenue Increases 512% Year-over-Year
March 27, 2019 — Medexus Pharmaceuticals Inc (CVE:MDP) (FRA:P731) CEO Ken d’Entremont provides an overview of the company and highlights its recent financial reporting. The company is the results of the recent amalgamation of three specialty pharmaceutical companies: Pediapharm Inc, …
Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor toxicity due to novel mechanism of action Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose …
Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement
LOS ANGELES, March 8, 2019 /CNW/ — Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in immunotherapy and immuno-oncology development pipelines, has executed a share exchange agreement with privately-held Edesa Biotech Inc., a Canadian company, and Edesa’s shareholders …
Forbius Announces First Patient Dosed in Phase 2a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Trial of AVID100, a Novel Anti-EGFR ADC
This trial will evaluate the efficacy of AVID100 in SCCHN patients with EGFR IHC 3+ tumors AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development 20% of SCCHN patients highly overexpress EGFR; no therapy is approved for …
Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Scleroderma Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
This trial will evaluate the safety and anti-fibrotic effects of AVID200 in diffuse cutaneous systemic sclerosis patients AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3 TGF-beta 1 & 3 are the principal drivers of fibrosis …
Forbius Collaborates with the Icahn School of Medicine at Mount Sinai & the Myeloproliferative Neoplasm Research Consortium to Evaluate AVID200
MPN-RC sponsored, NIH-supported Phase 1/2 trial in myelofibrosis to commence imminently TGF-beta is a central driver of bone marrow fibrosis in myelofibrosis AVID200 selectively inhibits TGF-beta 1 & 3, the principal fibrotic TGF-beta isoforms, while sparing TGF-beta 2, a positive …
Cardiac Dimensions Appoints Carmelo Mastrandrea as Vice President of Sales
Medical Device Industry Expert to Spearhead European Sales of the Carillon Mitral Contour System KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment …
Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor Best-in-class efficacy and safety potential by selectively targeting principal oncogenic TGF-beta isoforms Reverses immunosuppression and renders tumors sensitive to checkpoint blockade in pre-clinical models Jan. 7, 2019 …
Exact Imaging Wins 2019 “Life Science Company of the Year” from Life Science Ontario (LSO)
Exact Imaging’s Novel ExactVu™ Micro-Ultrasound System is Helping Urologists Worldwide Revolutionize Prostate Cancer Detection TORONTO, Nov. 22, 2018 /PRNewswire/ – Exact Imaging, the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, proudly announces this it has …
Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase 2b AURA-LV Study for Lupus Nephritis (LN)
AURA-LV is the first global active LN study to meet its primary endpoint and all of its 24-week pre-specified secondary endpoints Comprehensive mortality review concludes that deaths in the AURA-LV study appear to be unrelated to study drug and consistent …